Zura Bio Limited (ZURA) Stock Analysis & Investment Frameworks
Zura Bio Limited (ZURA) stock analysis on Invetso. Review Zura Bio Limited’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Zura Bio Limited Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Zura Bio Limited Key Financial Metrics
- Market Cap: $383.32M
- Revenue: $N/A
- ROE: -54.98%
- ROIC: -47.02%
- Dividend Yield: N/A
About Zura Bio Limited
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.